Vildagliptin

Overview

Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV ( DPP-IV ) inhibitor with an IC 50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Dipeptidyl Peptidase | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-14291
• CAS No.: 274901-16-5
• Molecular Formula: C17H25N3O2
• Molecular Weight: 303.40
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 100 mg/mL (329.60 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
• Availability: In-stock

Source

Original product source